Synchron Raises $200M to Advance Brain-Computer Interface Launch
Synchron has secured $200 million to accelerate pivotal trials and prepare for the commercial launch of its Stentrode brain-computer interface (BCI) system. The company aims to use these funds to expand testing and ready the device for market introduction.
About Brain-Computer Interface Devices
Brain-computer interface companies develop devices that capture and interpret brain signals to trigger actions, like hands-free control of digital devices. However, each device differs notably in design and approach.
Comparing Synchron and Neuralink
- Elon Musk’s Neuralink implants its device by surgically removing part of the skull.
- Synchron’s Stentrode is implanted via a minimally invasive catheter procedure.
- The two devices balance the invasiveness of implantation with the quality of signal capture.
Synchron’s first-generation Stentrode has 16 electrodes, while Neuralink’s N1 Implant features 1,024 electrodes. Despite fewer electrodes, the Stentrode enables people with severe paralysis to operate personal devices effectively.
Future Plans and Technology Strategy
The Series D funding positions Synchron to leverage the current device’s advantages and address its limitations over time. Alongside commercial launch preparations, the company is developing a next-generation transcatheter, high-channel, whole-brain interface.
Artificial intelligence plays a key role in this development. Synchron is building an AI team in New York City focused on training models that learn from brain data to decode thought in real time.
Synchron’s goal is to “decode thought in real time.”
By integrating AI with advanced brain interfaces, Synchron aims to improve communication and control for users with neurological impairments.
Author’s Summary
Synchron advances brain-computer interfaces with $200 million to promote commercial launch and AI-driven real-time thought decoding through its less invasive Stentrode device.